1. Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? 
Adrian G. Sacher, MD, Lisa W. Le, MSc, Natasha B. Leighl, MD, MMSc, FRCPC, Linda E. Coate, MD, MRCPI 
Journal of Thoracic Oncology 
Volume 8, Issue 3, Pages (March 2013)
DOI: /JTO.0b013e31827e2145
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1 Flow diagram of the study protocol.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31827e2145)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
The percentage of studies by decade, which explicitly exclude elderly patients among the 100 most cited phase III clinical trials in the treatment of advanced NSCLC. NSCLC, non–small-cell lung cancer.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31827e2145)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
The average median age of patients in highly cited phase III trials in advanced NSCLC by decade. There were four trials with a median patient age greater than 65 (○). NSCLC, non–small-cell lung cancer.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31827e2145)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

5. FIGURE 4
The average median age of patients in the 100 most cited phase III clinical trials in advanced NSCLC compared with the general population (—). NSCLC, non–small-cell lung cancer.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31827e2145)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions